RxDoctor Payments Data

Rhianon Iassogna Roman, APRN

Family · Derby, CTNPI 1457422057

Payments from drug & device makers

$1,939in general payments, 2019–2025

Across 88 payments — averaging $22.04 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Sumitomo Pharma America, Inc.$528
  • Johnson & Johnson$266
  • Tolmar, Inc.$202
  • Astellas Pharma US Inc$174
  • Bayer$115
  • 180 Medical, Inc.$101
  • plus $553 from 14 others

What the payments were for

  • Food & beverage$1,939100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,939 in reported general payments places this provider in the 80th percentile of 1,596 family providers in Connecticut.

See all family providers in Connecticut

Medicare billing

Part B allowed, 2024
$37,972
Medicare patients
136
Services billed
2,744

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
GemtesaVibegron155$122,343
MyrbetriqMirabegron63$47,999
Tamsulosin Hcl549$5,379
Methenamine Hippurate89$3,707
Cefpodoxime Proxetil52$2,553
Testosterone21$2,465
Solifenacin Succinate25$2,432
Dutasteride64$2,071
Doxazosin Mesylate175$1,401
Oxybutynin Chloride ErOxybutynin Chloride89$1,320
Estradiol16$1,147
Finasteride63$833
Ziprasidone Hcl20$713
Trospium Chloride18$708
NitrofurantoinNitrofurantoin Macrocrystal18$551

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Sumitomo Pharma America, Inc.Gemtesa$528$122,343155 claims
Astellas Pharma US IncMyrbetriq$174$47,99963 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 1,596 family providers in Connecticut.

Other family in Derby

See the full list for Connecticut

Where these figures come from

Is this you, or does something look wrong? →